Today: 2 July 2026
Browse Category

NYSE:LLY 21 April 2026 - 30 June 2026

Centessa (NASDAQ:CNTA) marks Eli Lilly (NYSE:LLY) CVR at 28 cents per dollar in last trade

Centessa (NASDAQ:CNTA) marks Eli Lilly (NYSE:LLY) CVR at 28 cents per dollar in last trade

As of 10:03 a.m. in New York, U.S. regular trading was open, following Nasdaq’s 9:30 a.m. to 4 p.m. ET session, but Centessa Pharmaceuticals plc had no new trades. Nasdaq’s CNTA market page showed no data, with the last price still at $40.50 from June 24 UTC. The last price is the one that counts now. Eli Lilly and Company is paying $38 in cash and a non-transferable CVR that could be worth as much as $9 a share. Based on CNTA’s last trade, the market valued that CVR at $2.50 before the ADS halted.
30 June 2026
··
Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop

Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop

At 05:01 EDT, the New York Stock Exchange cash session had not opened. NYSE lists a 9:30 a.m. to 4:00 p.m. ET core session, and its 2026 holiday list shows the next full U.S. market closure is July 3 for Independence Day observed. Eli Lilly and Company starts the week with a cleaner investor problem than most mega-cap drug stocks: the stock has already priced in a lot of good news. Friday’s 7.13% jump pushed Lilly to a record close of $1,208.12, and a 4:46 a.m. EDT pre-market quote showed the shares up another 1.69% at $1,228.52. WSJ data put Friday volume at 7.72 million shares, against a 65-day average of 3.25 million.
29 June 2026
··
Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land

Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land

Eli Lilly and Company closed at $1,208.12 on Friday, up $80.43. Markets in U.S. cash equities were closed Saturday, leaving Friday as the last pricing. About 7.73 million shares traded, coming in at roughly 2.5 times the average volume listed on Google Finance. Lilly’s blood-cancer drug didn’t just get a $76 billion re-rating overnight. What buyers paid for is the bigger Lilly trade—European oncology news, Medicare obesity coverage just ahead, and a health-care move while tech stumbled.
27 June 2026
··
Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly and Company jumped 6.5% to $1,200.98 by 1:46 p.m. EDT Friday, tacking on about $65.7 billion in market cap. Shares hovered close to the session’s high of $1,208.18. The stock was at 42.7 times earnings, with 3.6 million shares traded. The index math told more of the story. Lilly made up 15.84% of the Health Care Select Sector SPDR Fund as of June 25, State Street said. Based on that, Lilly’s move on Friday added about 1.03 percentage points to XLV—roughly 43% of the ETF’s 2.4% rise at one point.
26 June 2026
···
Centessa (NASDAQ:CNTA) final price leaves Lilly (NYSE:LLY) CVR at about 28% of max

Centessa (NASDAQ:CNTA) final price leaves Lilly (NYSE:LLY) CVR at about 28% of max

Centessa Pharmaceuticals plc shares were not trading live on Friday, but this wasn’t due to a holiday. Trading in New York was open at 10:04 a.m. EDT, with the Nasdaq’s regular session running 9:30 a.m. to 4:00 p.m. ET. There’s no market closure for June 26 on the 2026 holiday list. Centessa shares stopped trading after its buyout by Eli Lilly and Company closed. The Nasdaq Composite started off down 1.0% at 25,105.414 on Friday, but CNTA isn't part of the usual public action anymore.
26 June 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales

Novo Nordisk’s B shares jumped 2.6% to 307.75 Danish crowns on Tuesday. The stock is up 5.1% since Friday’s close and has gained 9.9% over three sessions. The OMXC25 index in Copenhagen fell 0.07%. Novo put a new number out for investors: 84,500. That’s roughly how many compounded semaglutide units iDexis supplied each month in South Africa, the company told a court. Novo says that’s more than it sold of Ozempic and Wegovy combined in the country. A court order on Monday barred iDexis from compounding, supplying, and marketing the semaglutide products while they’re under regulatory review. Compounding in this case refers to pharmacies preparing or adjusting a drug for patients. The court filing doesn’t clarify if a unit from iDexis matches a Novo pack, so there’s no way to turn the number into revenue.
24 June 2026
····
Nasdaq Futures Rise Ahead of CPI; Tech Buyers Step In

Nasdaq Futures Rise Ahead of CPI; Tech Buyers Step In

Nasdaq futures climbed Tuesday morning, pulling U.S. stock futures higher as traders bought back into tech ahead of a major inflation reading that could challenge the recovery. Wall Street is weighing whether Friday’s plunge in tech stocks was just a reset or the start of a bigger shakeout for the AI trade. Nasdaq 100 futures rose 0.76%, S&P 500 futures gained 0.44%, Dow futures added 120 points, or 0.24%, and Russell 2000 futures climbed 0.88%, according to delayed futures data.
9 June 2026
······
Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly heads into the U.S. pre-market Monday facing a fresh test of its trillion-dollar market cap after dropping new data on wider benefits from its upcoming obesity drugs. Shares ended Friday at $1,131.42, gaining 0.55%. The S&P 500 ETF lost 2.6%. The Health Care Select Sector SPDR ETF picked up 0.6% in the last quoted session. Timing is key. Lilly's not just facing questions about Zepbound and Mounjaro demand anymore. Now, investors want to know if retatrutide and Foundayo, the oral obesity pill, can turn the company’s obesity push into something bigger in cardiometabolic health. So it’s weight loss, yes, but also data in diabetes, sleep apnea and joint pain. Those numbers could help convince doctors and payers that Lilly’s drugs go beyond treating weight.
8 June 2026
Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly shares finished the week at a record high close, gaining 0.6% Friday at $1,131.42. On Saturday, the company put out late-stage results showing its retatrutide injection, still experimental, cut obstructive sleep apnea severity by 60.6% and reduced knee osteoarthritis pain by as much as 73.1% in obese adults. Monday’s open carries weight for Lilly. The stock ended up around 2.4% for the week, closing at $1,105.00 on May 29, but the broader market sold off late Friday. Next up is the reaction to fresh data, which may show if investors still want to push the top obesity play higher.
6 June 2026
···
CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics AG shares surged in early afternoon U.S. trade Thursday, up 11.7% at $58.15. Investors moved into gene-editing stocks. The Nasdaq name hit an intraday high of $59.00. About 2.0 million shares traded, putting its market cap close to $5.6 billion. Biotech stocks rallied beyond a single name. The SPDR S&P Biotech ETF gained 3.0%. Gene-editing stocks Intellia Therapeutics climbed 14.4%, Beam Therapeutics added 10.6% and Editas Medicine rose 9.4%. CRSP moved with the sector, not alone.
4 June 2026
·······
Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly & Co. is picking up Curevo Inc., LimmaTech Biologics AG and Vaccine Company Inc. in three cash acquisitions worth as much as $3.83 billion. With the deals, the U.S. drugmaker gets its hands on vaccine programs for shingles, staph infections and Epstein-Barr virus. Lilly’s move is drawing attention as the company looks to push the surge in GLP-1 drug sales into broader growth. Mounjaro posted $8.7 billion in sales in the first quarter and Zepbound added $4.2 billion, according to Reuters last month.
28 May 2026
···
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers. That’s suddenly important, with forecasts tightening up. Wall Street’s consensus sits around $617 million for first-quarter revenue, and EPS is pegged between 3 and 4 cents, according to public estimate trackers. Hims shares finished Friday’s regular session at $28.46, ticking up to $29.07 in after-hours trading.
11 May 2026
····
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned. This shift is significant for Novo, which has been working to regain investor trust after ceding space in the U.S. obesity market. Lilly has picked up share there with its injectable treatments and recently launched a pill of its own. GLP-1 drugs—these mimic a gut hormone involved in appetite regulation and blood sugar—have surged into one of pharma’s hottest growth segments.
6 May 2026
···
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Shares of Cabaletta Bio Inc. surged roughly 32% late Monday, buoyed by news of early results from a small cell-therapy trial and the announcement of a $150 million stock sale that counted Eli Lilly among its participants. Trading hit $3.895 on strong volume, topping out intraday at $4.04, according to market data. Share sales tend to draw flak from biotech investors worried about dilution, but Cabaletta’s deal played out differently. The company sold 51.7 million shares at $2.90 apiece—the at-the-market price allowed under Nasdaq rules. Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, along with fresh mutual and sovereign wealth funds, and Eli Lilly all took part.
4 May 2026
····
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly hiked its full-year outlook for both sales and profit Thursday, following a jump in quarterly revenue driven by strong uptake of its diabetes drug Mounjaro and obesity therapy Zepbound. First-quarter revenue climbed 56% to $19.8 billion, according to the Indianapolis-based company, with adjusted earnings coming in at $8.55 per share. Lilly’s numbers are drawing attention as the company looks to turn the worldwide surge in GLP-1 drugs — which mimic a gut hormone and help regulate appetite and blood sugar — into stronger sales, despite pricing headwinds. The company reported that higher sales volumes more than made up for lower realized prices, the figure Lilly pockets after rebates and discounts.
30 April 2026
··
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions. This figure is key: investors are watching the launch closely to gauge if Lilly can push past injectables like Zepbound and stay ahead in the obesity drug race. Pills may bring in patients who’d rather skip injections, though Novo already enjoys a head start—time on shelves, brand muscle, momentum.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment. Investors are watching the numbers closely, looking for signs that weight-loss pills might expand the market beyond injections. That could mean more out-of-pocket customers and possibly change the dynamic between the two main players in the GLP-1 drug space. GLP-1 drugs work by acting on a hormone linked to appetite and blood sugar. Pills offer a needle-free alternative, but injections are still projected to account for a big share of the market.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform. This shift is crucial for Hims, which is looking to step away from compounded versions—pharmacy-mixed imitations of branded drugs—right as U.S. regulators clamp down on the loopholes that allowed those products to proliferate during supply shortages. GLP-1s, a red-hot category of obesity and diabetes treatments known for curbing appetite and lowering blood sugar, now face a more competitive, cash-pay landscape. Lilly and Novo are slashing prices, doubling down on direct sales, and pushing harder into telehealth.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment. Hims is making a significant pivot, stepping back from its more controversial compounded GLP-1 model—where pharmacies tailor-make drugs for individual patients—and instead moving toward branded, FDA-approved options. Back in March, the company announced it would stop marketing compounded GLP-1s, striking a deal with Novo Nordisk to add Ozempic and Wegovy to its platform.
21 April 2026
·····
1 2 3 … 13

Stock Market Today

  • OpenAI Floats Giving U.S. Government 5% Equity Stake, IPO Pushed Back
    July 2, 2026, 4:04 AM EDT. OpenAI CEO Sam Altman pitched a plan to set aside 5% equity from top U.S. AI firms for a government fund, modeled after Alaska's Permanent Fund, the Financial Times reported. The idea comes as Washington boosts its presence in the sector-last year the government took a 10% stake in Intel. Sources said OpenAI's IPO is pushed to next year, while Anthropic could list in Q4. Altman's proposal is part of talks about national security and public returns from AI as the industry faces tighter regulation and export controls. Politicians like Donald Trump and Senator Bernie Sanders are in the mix.
Go toTop